Media coverage
5
Media coverage
Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Media name/outlet Indian Pharma Industry : Policies Country/Territory India Date 16/02/23 URL ct.moreover.com/?a=50026726508&p=1gw&v=1&x=V4zfien_fc8AGWra5Ez5xg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Media name/outlet InvestorsObserver Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001104781&p=1gw&v=1&x=MORWVid0-ldZFc2aXBpqOA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Media name/outlet Le Lezard.com Country/Territory Canada Date 13/02/23 URL ct.moreover.com/?a=50001088842&p=1gw&v=1&x=gxyt6ptx0PMnH58khLOnsA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Media name/outlet MarketScreener.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001099261&p=1gw&v=1&x=6MAdXTrIrxFRJ2cSfOZHAA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Media name/outlet Hugin - English Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50003748360&p=1gw&v=1&x=VeMyN2piR0zNAxeIdrrZlg Persons Mauricio Burotto